This poster was presented at the British Thoracic Oncology Group conference, 2025. It aims to elicit expert clinical judgements on important factors for treatment decisions in advanced ALK-positive NSCLC, clinical monitoring requirements for treatment, perceived toxicity of ALK-TKIs, best practices in shared decision-making and key clinical priorities.
Estimating health-state utility values for family-caregivers of patients with Duchenne muscular dystrophy using time trade-off valuation
Borecka O, Llewellyn S, Woollacott I, Richardson L, Fellows A, Lawrence J, Bottomley C, Biggane AM (JPRO, 2026)


Copy Link